mRNA-2808 / Moderna - LARVOL DELTA

Moderna, Inc…announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the Company's investigational mRNA-based T-cell engager (TCE) for participants with relapsed or refractory multiple myeloma (RRMM). (ACCESS Newswire)

Trial status • Multiple Myeloma

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - P1/2 | N=166 | Recruiting | Sponsor: ModernaTX, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Malignancies • Multiple Myeloma • Oncology

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - P1/2 | N=166 | Not yet recruiting | Sponsor: ModernaTX, Inc.

New P1/2 trial • Hematological Malignancies • Multiple Myeloma • Oncology